From Personal Pain to Global Progress: A New Era in Advanced Medicine

PHILADELPHIA, PA – July 14, 2026 – This September, two of the most powerful forces in modern medicine—the patient who became a symbol of hope and the father who became a biotech CEO—will converge in Philadelphia. The occasion is the Emily Whitehead Foundation's 2026 Believe Ball, an event that transcends the typical charity gala. It represents a critical inflection point in the journey of advanced therapies, moving the conversation from the miracle of the initial breakthrough to the complex challenge of global access. The announcement that John F. Crowley, the formidable head of the Biotechnology Innovation Organization (BIO), will deliver the keynote address underscores the event's significance. It signals a united front between patient advocates and industry titans, both driven by deeply personal histories to reshape the future of medicine.

A Convergence of Crusades

At the heart of this movement are two extraordinary stories that have become modern medical parables. The first is that of Emily Whitehead, who, at five years old, faced a relapsed acute lymphoblastic leukemia that had exhausted all standard treatments. In 2012, at the Children's Hospital of Philadelphia, she became the first child in the world to receive a revolutionary experimental treatment called CAR T-cell therapy. The therapy, which re-engineers a patient's own immune cells to fight cancer, saved her life. Today, Emily is a thriving young adult, her survival a living testament to the potential of cellular medicine.

Her journey spurred her parents, Tom and Kari Whitehead, to establish the Emily Whitehead Foundation, a leading voice for patient access and support. The foundation's work is animated by a simple, powerful goal: to turn Emily's story into countless more survivor stories.

This mission finds a powerful ally in John F. Crowley. His own crusade began in 1998 when two of his children were diagnosed with Pompe disease, a rare and fatal neuromuscular disorder. Refusing to accept their prognosis, Crowley left his corporate job, co-founded a biotech startup, Novazyme Pharmaceuticals, and raced against time to develop a treatment. His family's incredible journey, which ultimately saved his children's lives, was chronicled in the book "The Cure" and the major motion picture "Extraordinary Measures." Today, as the President and CEO of BIO, the world's largest biotech advocacy organization, Crowley's personal history informs his professional mandate to champion innovation and accelerate the delivery of new medicines.

"John Crowley embodies the very essence of 'Believe,'" said Tom Whitehead, co-founder of the Emily Whitehead Foundation. "His story reminds us that with enough determination and innovation, we can change the course of medicine to save the lives of those we love. We look forward to welcoming John at the Believe Ball to share his vision with our growing community of Warrior patients, their families and industry partners."

The Next Frontier: From Breakthrough to Bedside

The Believe Ball serves as more than a fundraiser; it is a strategic nexus where the human element of disease meets the industrial engine of innovation. The challenge is no longer just proving that therapies like CAR-T can work, but ensuring they can reach the patients who need them. This is the complex world "beyond the launch," fraught with logistical, financial, and regulatory hurdles.

Advanced therapies are staggeringly expensive, often costing hundreds of thousands of dollars per patient before factoring in hospitalization and managing side effects. This creates immense access barriers, as insurance coverage remains inconsistent and patients can face crippling out-of-pocket costs. Furthermore, the complex, personalized manufacturing process and the need for highly specialized medical centers create significant geographical disparities, leaving many patients without a viable path to treatment.

These are precisely the issues Crowley is tackling at BIO. Under his leadership, the organization has sharpened its focus on human health and launched patient-centered campaigns like "Fight of Our Lives" to highlight the urgency of sustaining biotech innovation. He is a vocal advocate for modernizing the U.S. Food and Drug Administration (FDA) to create more predictable and streamlined regulatory pathways. This includes supporting initiatives like the Advanced Manufacturing Technologies (AMT) Designation Program, which aims to accelerate the approval of novel manufacturing platforms that could eventually lower costs and scale production for cell therapies.

The Believe Ball provides a unique forum to advance this agenda, placing policymakers, scientists, and pharmaceutical executives in the same room as the families whose lives hang in the balance. It's a powerful reminder that behind every data point and regulatory filing is a person waiting for a cure.

Philadelphia: The Crucible of 'Cellicon Valley'

It is no coincidence that this pivotal gathering is taking place in Philadelphia. The city is not merely the backdrop for Emily Whitehead's story; it is the epicenter of the cell and gene therapy revolution. Dubbed "Cellicon Valley," the region has cultivated a dense, world-class ecosystem for advanced medical research and commercialization. This ecosystem is anchored by powerhouse institutions like the University of Pennsylvania and the Children's Hospital of Philadelphia (CHOP), whose pioneering research laid the foundation for the first CAR T-cell therapy approvals.

The city's leadership extends beyond a single breakthrough. It is home to Spark Therapeutics, which developed the first FDA-approved gene therapy for an inherited disease, and a burgeoning cluster of startups and established companies all focused on the next wave of medical innovation. This concentration of scientific talent, research infrastructure, and venture capital has made Philadelphia a global hub for turning laboratory discoveries into life-saving treatments. Hosting the Believe Ball here honors the city's historical role while reinforcing its position as a continuing nexus for the future of medicine, creating a palpable sense that the solutions to global challenges can be forged in the very place where the first miracle occurred.

Activating Cures and Honoring Hope

While the keynote address will set the tone, the Believe Ball's impact is woven throughout the evening's agenda. The event is designed to foster connection and inspire action. Through its "Stories of Hope" segment, the gala elevates the lived experiences of patients and families, ensuring their voices remain at the center of the conversation. The foundation will also present its Embassador Awards—the Bill Ludwig Pioneer Award and the Thomas G. Whitehead Beacon of Hope Award—to recognize individuals who have made significant contributions to the field.

Crucially, the event translates inspiration into tangible support through The Nicole Gularte Fight for Cures Grant, an annual grant dedicated to funding research in advanced therapies and patient support. With the backing of title sponsor Novartis and other industry partners, the foundation is channeling the funds raised directly into its mission to "activate cures." This holistic approach—combining advocacy, community building, and direct research funding—is how the Emily Whitehead Foundation aims to build a world where a story like Emily's is not the exception, but the expectation.